Cargando…

Edoxaban, a Factor Xa-Specific Direct Oral Anticoagulant, Significantly Suppresses Tumor Growth in Colorectal Cancer Colon26-Inoculated BALB/c Mice

Introduction Certain low-molecular-weight heparins have been reported to reduce tumor growth and metastasis in tumor cell-inoculated mouse models and cancer patients. Recently, direct oral anticoagulants (DOACs) have been widely used in patients with thromboembolism. This study was aimed at investi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hiramoto, Keiichi, Akita, Nobuyuki, Nishioka, Junji, Suzuki, Koji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Georg Thieme Verlag KG 2023
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9825203/ https://www.ncbi.nlm.nih.gov/pubmed/36751299 http://dx.doi.org/10.1055/s-0042-1758855

Ejemplares similares

Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa
por: Parasrampuria, Dolly A., et al.
Publicado: (2015)

Edoxaban: An Update on the New Oral Direct Factor Xa Inhibitor
por: Bounameaux, Henri, et al.
Publicado: (2014)

Erratum to: Edoxaban: An Update on the New Oral Direct Factor Xa Inhibitor
por: Bounameaux, Henri, et al.
Publicado: (2014)

Determination of Anti-Xa Inhibitor Plasma Concentrations Using a Universal Edoxaban Calibrator
por: Burger, Annika, et al.
Publicado: (2023)

Factor Xa Inhibitory Profile of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban Does Not Fully Reflect Their Biologic Spectrum
por: Siddiqui, Fakiha, et al.
Publicado: (2019)

Factor Xa inhibitor, edoxaban ameliorates renal injury after subtotal nephrectomy by reducing epithelial‐mesenchymal transition and inflammatory response
por: Fang, Lixin, et al.
Publicado: (2022)

A universal anti‐Xa assay for rivaroxaban, apixaban, and edoxaban measurements: method validation, diagnostic accuracy and external validation
por: Willekens, Guido, et al.
Publicado: (2021)

Impact of Renal Function on Anti-factor Xa Activity Concentrations with Edoxaban Use in Patients with Non-valvular Atrial Fibrillation
por: Ono, Ryohei, et al.
Publicado: (2022)

Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban
por: Ansell, Jack E., et al.
Publicado: (2017)

Pharmacokinetics of anticoagulant edoxaban in overdose in a Japanese patient transported to hospital
por: Adachi, Koichiro, et al.
Publicado: (2020)

The Tick-Derived Anticoagulant Madanin Is Processed by Thrombin and Factor Xa
por: Figueiredo, Ana C., et al.
Publicado: (2013)

Andexanet alfa for reversal of factor Xa inhibitor-associated anticoagulation
por: Carpenter, Elise, et al.
Publicado: (2019)

Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein, an Efflux Transporter, on the Pharmacokinetics of Edoxaban, an Oral Factor Xa Inhibitor
por: Mendell, Jeanne, et al.
Publicado: (2013)

Sustained safe and effective anticoagulation using Edoxaban via percutaneous endoscopic gastrostomy
por: Galli, Mattia, et al.
Publicado: (2019)

Cost-Effectiveness of Anticoagulation in Patients with Nonvalvular Atrial Fibrillation with Edoxaban Compared to Warfarin in Germany
por: Krejczy, Martin, et al.
Publicado: (2015)

Andexanet Alfa for Specific Anticoagulation Reversal in Patients with Acute Bleeding during Treatment with Edoxaban
por: Benz, Alexander P., et al.
Publicado: (2022)

Ortholog Alleles at Xa3/Xa26 Locus Confer Conserved Race-Specific Resistance against Xanthomonas oryzae in Rice
por: Li, Hong-Jing, et al.
Publicado: (2012)

Accuracy of a Single, Heparin-Calibrated Anti-Xa Assay for the Measurement of Rivaroxaban, Apixaban, and Edoxaban Drug Concentrations: A Prospective Cross-Sectional Study
por: Meihandoest, Tamana, et al.
Publicado: (2022)

Bedside anti-Xa measurement for therapeutic assessment of a prophylactic anticoagulation regimen
por: Dewulf, B, et al.
Publicado: (2013)

The Role of Factor Xa-Independent Pathway and Anticoagulant Therapies in Cancer-Related Stroke
por: Kim, Hyung Jun, et al.
Publicado: (2021)

Anticoagulation treatment and prophylactic edoxaban for cerebral sinus venous thrombosis in an adolescent with acute lymphoblastic leukemia
por: Koganesawa, Masaya, et al.
Publicado: (2021)

The edoxaban‐M4 metabolite and measurement of edoxaban by chromogenic assays in human plasma
por: Siriez, Romain, et al.
Publicado: (2022)

Superior mesenteric vein thrombosis treated with edoxaban
por: Hashizume, Yutaka, et al.
Publicado: (2017)

Tumour inoculation site-dependent induction of cachexia in mice bearing colon 26 carcinoma
por: Matsumoto*, T, et al.
Publicado: (1999)

Reversal of edoxaban-induced anticoagulation by the four-factor prothrombin complex concentrate Beriplex(® )in a rabbit model
por: Herzog, E, et al.
Publicado: (2014)

Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants including edoxaban
por: Härtig, Florian, et al.
Publicado: (2021)

Edoxaban, a direct oral factor Xa inhibitor, ameliorates coagulation, microvascular thrombus formation, and acute liver injury in a lipopolysaccharide-induced coagulopathy model in rats
por: Morishima, Yoshiyuki, et al.
Publicado: (2021)

ENGAGE AF: Effective anticoagulation with factor Xa in next generation treatment of atrial fibrillation
por: Kaba, Riyaz A, et al.
Publicado: (2013)

Structure‐function of anticoagulant TIX‐5, the inhibitor of factor Xa‐mediated FV activation
por: Maag, Anja, et al.
Publicado: (2021)

Personalized prophylactic anticoagulation in hospitalized patients with Covid-19 – The role of anti-Xa monitoring
por: Kofteridis, Diamantis P., et al.
Publicado: (2021)

Andexanet alfa effectively reverses edoxaban anticoagulation effects and associated bleeding in a rabbit acute hemorrhage model
por: Lu, Genmin, et al.
Publicado: (2018)

Deep Vein Thrombosis in Severe Motor and Intellectual Disabilities Patients and Its Treatment by Anticoagulants of Warfarin Versus Edoxaban
por: Ohmori, Hiromitsu, et al.
Publicado: (2019)

Periprocedural anticoagulation in the uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation (ELIMINATE-AF) trial
por: Hohnloser, Stefan H, et al.
Publicado: (2020)

Effect of edoxaban compared with other oral anticoagulants for stroke prevention in patients with atrial fibrillation: A meta-analysis
por: Zhang, Bailin, et al.
Publicado: (2023)

Autophagy-Like Cell Death Regulates Hydrogen Peroxide and Calcium Ion Distribution in Xa3/Xa26-Mediated Resistance to Xanthomonas oryzae pv. oryzae
por: Cao, Jianbo, et al.
Publicado: (2019)

Effect of dexamethasone on direct Xa-inhibitor oral anticoagulant plasma levels in patients with COVID-19
por: Bosch, Floris T.M., et al.
Publicado: (2021)

Major bleeding during oral anticoagulant therapy associated with factor V activation by factor Xa
por: Maag, Anja, et al.
Publicado: (2021)

Edoxaban in the Evolving Scenario of Non Vitamin K Antagonist Oral Anticoagulants Imputed Placebo Analysis and Multiple Treatment Comparisons
por: Verdecchia, Paolo, et al.
Publicado: (2014)

Edoxaban Vs. Low Molecular Weight Heparin As Anticoagulant Therapy in Hospitalized Patients with Atrial Fibrillation and COVID-19 Infection
por: Olivera, Pável E, et al.
Publicado: (2020)

Use of multiple laboratory tests including anti-factor Xa to optimally manage anticoagulation during ECMO
por: Honore, Patrick M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2rhjq0224g54rmen03dgrsdn27